Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024
Cooley M&A
JANUARY 23, 2024
Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales. Collaborate or buy?’ Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value. Multiple factors, as it turns out. We’ll keep you posted.
52 
Let's personalize your content